Titolo progetto: ALBINO - Effect of ALlopurinol in addition to hypothermia for hypoxic-ischemic Brain Injury on Neurocognitive Outcome.

Programma di finanziamento: Horizon 2020

Responsabile scientifico: prof.ssa Paola Cogo

Ruolo del DAME: partner

Descrizione generale:

The ALBINO study aims at showing the efficacy of the drug “allopurinol”. For this purpose, 900 newborns who have suffered from oxygen deficiency during birth will be examined. Even in large hospitals there are fewer than five such babies per year. That is why it is necessary to conduct an extensive multicenter international study in order to recruit the patient number.

The drug, which has traditionally been used to treat chronic gout in adults, reduces the uric acid concentration in the blood. For a long time the exact effect of “allopurinol” on patients with oxygen deficiency was unknown. Over the last few years scientists, in a first step, were able to describe the mechanisms which lead to brain damage as a result of oxygen deficiency. These processes do not arise immediately in the deficiency situation but within the first hours after the incident. Thus, there is a “therapeutic window” for treatments which might protect the brain cells?

Partner del progetto:

Date inizio e fine progetto: 01.01.2017 – 01.07.2020

Budget totale del progetto: 6.307.599,50 €

Sito web: https://www.albino-study.eu/index.php

Contatti: paola.cogo@uniud.it